XTL Biopharmaceuticals Ltd

XTLB

Company Profile

  • Business description

    XTL Biopharmaceuticals Ltd is an intellectual property-based company focused on the development, management, and commercialization of intellectual property. The Company is engaged in biotechnology through its subsidiary Psyga Bio and in the biopharmaceutical industry with hCDR1, a novel compound working via a novel mechanism of action for the treatment of Systemic Lupus Erythematosus (SLE) and a potential treatment for Sjogren's syndrome (SS). It focuses on the acquisition and development of proprietary products and late-stage pharmaceutical product candidates for the treatment of unmet clinical needs.

  • Contact

    85 Medinat Hayehudim Street
    Hertzlia4676670
    ISR

    T: +972 542288897

    E: [email protected]

    https://www.xtlbio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    5

Stocks News & Analysis

stocks

Why don’t good returns guarantee a 5-star rating?

Amy Arnott explains how Morningstar’s stock ratings work.
stocks

Despite post earnings rally ASX share still cheap

Lifting our 2028 earnings estimate by 20%.
stocks

Overvalued ASX share has overly ambitious profit target

We think the new profit target is aggressive and unlikely to be met.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,979.3018.00-0.20%
CAC 408,216.78135.22-1.62%
DAX 4026,045.37553.27-2.08%
Dow JONES (US)50,759.42848.75-1.64%
FTSE 10010,689.87191.68-1.76%
HKSE23,508.17245.67-1.03%
NASDAQ24,328.38181.38-0.74%
Nikkei 22558,860.43801.59-1.34%
NZX 50 Index14,309.082.120.01%
S&P 5007,340.5376.06-1.03%
S&P/ASX 2008,863.3019.90-0.22%
SSE Composite Index3,584.5817.99-0.50%

Market Movers